RT Journal Article
SR Electronic
T1 Illness and Fatality Risks of COVID-19 of General Public in Hubei Provinces and Other Parts of China
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.25.20027672
DO 10.1101/2020.02.25.20027672
A1 Li, Hongdou
A1 Wang, Shuang
A1 Zhong, Fan
A1 Bao, Wuyin
A1 Li, Yipeng
A1 Liu, Lei
A1 Wang, Hongyan
A1 He, Yungang
YR 2020
UL http://medrxiv.org/content/early/2020/02/27/2020.02.25.20027672.abstract
AB New coronavirus 2019-nCOV poses a big challenge for global public health in early 2020. Coronavirus Disease 2019 (COVID-19) caused by the virus rapidly spreads all over the world and takes thousands of lives in just two months. To assess illness and fatality risk of the viral infection is exceedingly helpful to ensure effective management of the general public and patients in the outbreak. Therefore, it is critical to quantify illness and fatality risk of COVID-19 for the general public. In this report, we investigate the illness and fatality risk of the infection by analyzing the age composition of 5319 infected patients, 76 mortality cases, and 1,144,648 individuals of the general public in China. Our result shows a relatively low illness risk for young people but a very high fatality risk for seniors. Notably, fatality risk could be as high as 0.48 for people older than 80 years. Furthermore, our study suggests that a good medical service can effectively reduce the mortality rate of the viral infection to 1% or less.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by grants from National Natural Science Foundation of China (Grant No. 31871255 and 91731310 to Y.H.) and Shanghai Municipal Science and Technology Major Project (Grant No. 2017SHZDZX01).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data was avaliable upon request.